Loading…
H.R. 8032119th CongressIn committeeLatest action Mar 20, 2026Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
Medicare would pay separately for newer cancer drugs costing $350/day or more instead of folding them into one bundled payment.
50-second read · 5 questions answered below
This bill changes how Medicare pays for certain cancer drugs and biologics given in outpatient settings. If a cancer treatment was FDA-approved on or after January 1, 2008, and its estimated daily cost reaches or exceeds $350, Medicare must pay for it separately rather than bundling it into the overall visit payment. That $350 threshold would increase each year with inflation, and the separate payment would generally be based on the drug's average sales price.
This bill affects hospitals and other outpatient providers that give these cancer treatments. Medicare patients who receive costly newer cancer therapies are also affected.
Under the current bundled system, hospitals may not be fully covered for the cost of expensive newer drugs. If providers cannot cover those costs, some patients could lose access to these therapies.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.